Already approved to treat four rare diseases, AstraZeneca’s Ultomiris has shown its ability against another rare disorder, ...

AZN's Ultomiris hits key goal in IgAN study, showing early proteinuria reduction as it eyes accelerated approval in major ...

When young adults are asked to recall their drinking habits, their recollections may not always match what actually happened ...

Positive high-level results from a prespecified interim analysis of the I CAN Phase III trial showed that Ultomiris (ravulizumab) met its primary ...

When young adults are asked to recall their drinking habits, their recollections may not always match what actually happened ...

ABU DHABI, 21st April, 2026 (WAM) -- M42 has announced the results of a national study conducted in partnership with the Department of Health – Abu Dhabi, highlighting the pivotal role of genomics in ...

Sleep affects nearly every system in the human body – but few sleep experiences are as disorienting, or as poorly understood, ...

The treatment landscape of generalised myasthenia gravis, a prototypic antibody-mediated disorder of the neuromuscular junction, has considerably evolved in the past 8 years.1 The approval of targeted ...

As published in The Lancet and presented at AAN, NIMBLE trial met its primary and key secondary endpoints at week 24, demonstrating potential ...

Our experience has taught us that innovation without deep human-centered caution can be as dangerous as the trauma itself,” said Maya Shany, Israeli youth delegate.

Jazz Pharmaceuticals plc  today announced that the Company and its partners will present three rapid oral and seven poster presentations at the American Society of Clinical Oncology (ASCO) Annual ...

Objective Cardiovascular diseases are a leading cause of morbidity and mortality in SLE. In this target population, ...